Clinical Trials Logo

Neurologic Autoimmune Disease clinical trials

View clinical trials related to Neurologic Autoimmune Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05204459 Recruiting - Multiple Sclerosis Clinical Trials

MS-ResearchBiomarkerS

MS-ReBS
Start date: November 11, 2021
Phase:
Study type: Observational

This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.

NCT ID: NCT00716066 Active, not recruiting - Myasthenia Gravis Clinical Trials

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.